🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Super star cardiology fellow Dr Alice Haouzi is presenting important findings from our work on Cleveland Clinic experience of fungal endocarditis CCF Cardiology Fellows Cleveland Clinic Heart, Vascular & Thoracic @CleClinicLCM Haytham Elgharably Shinya Unai Brian Griffin #ACC2025 #ACCinTouch

Excellent moderated poster and Q&A sessions by Aravinthan Vignarajah , Ang Qi Xuan (Darian) , and Yeo Yong Hao at ACC.25 today 🔥 American College of Cardiology #Cardiotwitter

Some amazing moments from #ACC25 Always enjoy the great opportunity to reconnect with mentors and friends while learning the latest in cardiology! 🫀 American College of Cardiology

From #ACC25 and Cleveland Clinic Heart, Vascular & Thoracic Aravinthan Vignarajah Min Choon Tan Kamala Tamirisa MD Oussama Wazni Justin Z Lee, #GLP1RA use was associated with reduced all-cause mortality and reduced hospitalization among patients with #T2D and comorbid #AFib. thecardiologyadvisor.com/reports/glp1-r…

In this week’s #EaglesEyeView, Dr. Kim Eagle looks at the major trials & presentations from #ACC25. This episode includes coverage of practice-changing & practice-validating trials including: SMART-CHOICE 3, STRIDE, RIVAWAR, & more. 🎧 Tune in here: bit.ly/4cloaij

Excited to present 9 studies from our team at #HRS2025! Topics range from AF in pregnancy & sarcoidosis to TAVR-induced AV block and VT ablation in HFrEF. #EPeeps #HRS2025

#HRS2025 Thrilled to share that our team is contributing 9 abstracts this year! One of our highlights - “Exploring the Effect of Tirzepatide in AF” - has been selected as a Featured Poster and included in the official HRS Press Kit 🔥Excited to see you at our presentation series!

Incredible experience at #HRS2025! Huge thanks to Justin Z Lee for the amazing mentorship and support.

Excited to share our latest work on arrhythmias in pregnancy/postpartum! DOACs were linked to lower mortality vs aspirin, and short-term antithrombotic use (<3mo) to less bleeding/hospitalizations. Important questions ahead! #CardioTwitter #CardioObstetrics

From #HRS2025: There are improved all-cause mortality, rhythm control, and adverse cardiac event outcomes in patients being treated with #tirzepatide who have #AFib. Heart Rhythm Society Cleveland Clinic Heart, Vascular & Thoracic Min Choon Tan Aravinthan Vignarajah Andrea Russo Oussama Wazni Justin Z Lee bit.ly/3SemnCg

Excited to share our new paper in European Society of Cardiology Journals! 🔍 GLP-1 receptor agonists were linked to more favorable outcomes in patients with ventricular arrhythmias — highlighting their potential as a novel therapy in this high-risk group. 📑: doi.org/10.1093/europa… #EPeeps #Europace

Three-Year Outcomes of Glucagon-like Peptide-1 Agonists in Atrial Fibrillation with Sarcoidosis and Diabetes Min Choon Tan heartrhythmjournal.com/article/S1547-…

Hot off the press in HeartRhythm 🔥 Can GLP-1 RA do more than control diabetes in AF pts with sarcoidosis—a relatively rare but challenging group? 🔍Our PSM analysis of 6,359 pts shows lower odds of all-cause death, cardiac arrest & acute HF with GLP-1 RA use. #GLP1RA #AF

Exploring the effects of Tirzepatide in Atrial Fibrillation. Min Choon Tan Justin Z Lee #EPeeps #HRS2025

Just published: Our new case series in Case Reports in Oncological Medicine highlights diagnostic and therapeutic challenges of cardiac metastases—rare, but clinically significant entity. #CardioOncology #MedTwitter #Oncology #Cardiology 📄 doi.org/10.1155/crom/7…

Check out our interesting case in Journal of Electrocardiology: ICD-induced ventricular arrhythmia from masked PVCs and R-on-T pacing in cardiac sarcoidosis. Highlights the importance of tailored device programming. 📝 doi.org/10.1016/j.jele…

🚨 Fresh off the press Thrilled to share our new publication in JAMA Network Open 📢 In a real-world cohort of patients with cirrhosis, SGLT2 inhibitor use was associated with: 📉 ↓ Serious liver events HR: 0.68 (95% CI, 0.66–0.71), p < .001 📉 ↓ All-cause hospitalizations

🔥 Hot off the press: SGLT2i may offer clinical benefit in pulmonary hypertension by lowering all-cause mortality, right heart failure, and hospital admission. DOI: doi.org/10.1177/175346…

📢New findings from a large retrospective cohort: In >44K patients with #MultipleMyeloma & #Type2Diabetes, SGLT2 inhibitors were associated with: ✅ 45% lower all-cause mortality ✅ 28% lower hospitalizations ✅ 30% lower VTE risk tandfonline.com/eprint/T3ARPZM…

In collaboration with Broad Clinical Labs & Mass General Brigham Lab for Molecular Medicine, Everygene (everygene.com) is now offering nationwide *no-cost* genetic testing for patients with suspected genetic cardiomyopathy prnewswire.com/news-releases/… Broad Institute